← Back to Search

Cannabidiol 600mg for Opioid Use Disorder

Phase 2
Waitlist Available
Research Sponsored by Brigham and Women's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up visit 2 and 3 (at least 1 week apart)
Awards & highlights

Study Summary

The purpose of this study is to determine the impact of cannabidiol on reward- and stress-related neurocognitive processes among individuals with opioid use disorder on buprenorphine or methadone treatment.

Eligible Conditions
  • Opioid Use Disorder

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~visit 2 and 3 (at least 1 week apart)
This trial's timeline: 3 weeks for screening, Varies for treatment, and visit 2 and 3 (at least 1 week apart) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Cue-reactivity
Secondary outcome measures
Attentional Bias
Decision Making
Delayed Discount
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Cannabidiol 600mgExperimental Treatment1 Intervention
All subjects will receive 600mg of oral cannabidiol in a double-blind fashion. Cannabidiol will be provided using Epidiolex™ oral solution 100mg/mL. Following administration, a battery of tests will be conducted to examine reward- and stress-related neurocognitive processes.
Group II: PlaceboPlacebo Group1 Intervention
All subjects will receive a matching placebo in a double-blind fashion. Following administration, a battery of tests will be conducted to examine the impact on reward- and stress-related neurocognitive processes.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cannabidiol 100 MG/ML [Epidiolex]
2022
Completed Phase 2
~20

Find a Location

Who is running the clinical trial?

Harvard Medical School (HMS and HSDM)OTHER
195 Previous Clinical Trials
1,316,014 Total Patients Enrolled
Brigham and Women's HospitalLead Sponsor
1,605 Previous Clinical Trials
11,467,281 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Cannabidiol on Reward- and Stress-related Neurocognitive Processes in Individuals With Opioid Use Disorder
Joji Suzuki, MD 2022. "Cannabidiol on Reward- and Stress-related Neurocognitive Processes in Individuals With Opioid Use Disorder". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04982029.
~5 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top